Segal Cancer Center, Lady Davis Institute for Medical Research and Departments of Oncology and Medicine, McGill University, Montréal, QC H3T 1E2, Canada.
Segal Cancer Center, Lady Davis Institute for Medical Research and Departments of Oncology and Medicine, McGill University, Montréal, QC H3T 1E2, Canada.
Cancer Cell. 2019 Jul 8;36(1):3-5. doi: 10.1016/j.ccell.2019.06.004.
In this issue of Cancer Cell, Fedoriw and colleagues characterize a potent reversible inhibitor of type I PRMTs, GSK3368715, with anti-proliferative effects on numerous cancer types. Using a combination of GSK3368715 with PRMT5 inhibitors, the authors show that a threshold of overall arginine methylation reduction needs to be achieved for synergistic anti-tumor activity.
在本期《癌细胞》中,Fedoriw 及其同事对一种有效的 I 型 PRMTs 可逆抑制剂 GSK3368715 进行了描述,该抑制剂对多种癌症类型具有抗增殖作用。作者通过将 GSK3368715 与 PRMT5 抑制剂联合使用,表明需要达到整体精氨酸甲基化降低的阈值才能实现协同抗肿瘤活性。